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Cancer is a complex, multiscale process involving interactions at intracellular, intercel-
lular and tissue scales that are in turn susceptible to microenvironmental changes. Each
individual cancer cell within a cancer cell mass is unique, with its own internal cellular
pathways and biochemical interactions. These interactions contribute to the functional
changes at the cellular and tissue scale, creating a heterogenous cancer cell popula-
tion. Anticancer drugs are effective in controlling cancer growth by inflicting damage to
various target molecules and thereby triggering multiple cellular and intracellular path-
ways, leading to cell death or cell-cycle arrest. One of the major impediments in the
chemotherapy treatment of cancer is drug resistance driven by multiple mechanisms,
including multi-drug and cell-cycle mediated resistance to chemotherapy drugs. In this
article, we discuss two hybrid multiscale modelling approaches, incorporating multiple
interactions involved in the sub-cellular, cellular and microenvironmental levels to study
the effects of cell-cycle, phase-specific chemotherapy on the growth and progression of
cancer cells.
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1. Introduction
Even with many important clinical and technological advancements in detecting
and treating cancer, cure and control of many forms of cancer remain the greatest
challenge to clinicians and scientists. In most cases, chemotherapy is used alone or in
combination with other anticancer treatments such as radiotherapy and surgery to
control a growing tumour. However, drug resistance driven by multiple mechanisms,
including multi-drug and cell-cycle mediated resistances to chemotherapy drugs con-
tinues to be a major barrier for the treatment failure in human malignancies1,2.
Several recent experimental studies have indicated the fundamental role of intratu-
moural heterogeneity as a driving source for the resistance to multiple chemother-
1
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apeutic drugs 3–4. One of the major reasons for this intratumoural heterogeneity
is the intracellular perturbations in biochemical kinetics and heterogeneity in the
tumour microenvironment that seriously impair the drug efficacy1. Hence, under-
standing various mechanisms involved in the development of drug resistance and,
devising drugs and protocols to target these mechanisms are significant steps in
overcoming drug resistance, where clinically driven computational models can play
an important role5–6.
The two main factors that contribute to the intra-tumoural heterogeneity are in-
ternal cell-cycle dynamics and the surrounding oxygen concentration. The cell-cycle
mechanism through which the cells duplicate consists of several transition phases of
varying lengths and check points and is mainly divided into four phases. As most of
the chemotherapeutic drugs that are administered to treat human malignancies are
cell-cycle phase specific, they spare some of the cells that are in the non-targeted
phase, causing a cell-cycle mediated drug resistance2. Cell-cycle dynamics are also
further influenced by the external microenvironmental conditions, especially the
availability of oxygen. Experimental evidence shows that hypoxia (lack of oxygen)
can upregulate the expressions of some of the cyclin dependent kinase inhibitors such
as p21 and p27, resulting in a prolonged cell-cycle time or even cell-cycle arrest7,8.
This further contributes to the cell-cycle heterogeneity and cell-cycle phase specific
drug resistance. Here, we discuss a multiscale mathematical model, incorporating
some of these cellular heterogeneities to understand and study their role in inducing
chemotherapeutic drug resistance.
The multiscale complexity of cancer progression warrants a multiscale mod-
elling approach to produce truly clinically useful and predictive mathematical mod-
els. Previously, Powathil et al.5 developed a multiscale mathematical model of
chemotherapy treatment, incorporating cell-cycle mediated intracellular heterogene-
ity and external oxygen heterogeneity to study the effects of cell-cycle, phase-specific
chemotherapy and its combination with radiation therapy9. It has been shown that
an appropriate combination of cell-cycle specific chemotherapeutic drugs with radi-
ation delivery could effectively be used to control tumour progression. There have
been several mathematical and computational modelling approaches developed to
study the occurrence of drug resistance 10–11. These approaches help to understand
and to some extent analytically quantify various biological processes. Furthermore,
it can also be used as a tool to analyse and design drug development experiments
and clinical trials. In this article, we discuss the multiscale mathematical model
developed by Powathil et al.5 and two different computational approaches to im-
plement the developed model. Further, we use it to study the effects of cell-cycle
phase-specific chemotherapeutic drugs on a growing tumour population with intra-
tumoral heterogeneities6.
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2. Modelling Cancer Growth: Multiple Scales Involved
Cancer growth is a complicated multiscale disease involving many interrelated pro-
cesses that occur across a wide range of spatial and temporal scales, from the intra-
cellular level to the tissue level. Consequently, a multiscale modelling approach is
needed to capture the key processes that are occurring at these different spatial and
temporal scales and couple them in an appropriate manner. Here we discuss a hybrid
multiscale model developed by Powathil et al.5 that analyses the spatio-temporal
dynamics at the level of individual cells, linking individual cell behaviour with the
macroscopic behaviour of cell/tissue organisation and the microenvironment. The
model captures the intracellular molecular dynamics of the cell-cycle pathway and
the changes in oxygen dynamics within the tumour microenvironment. It is then
used to study the the impact of oxygen heterogeneity on the spatio-temporal pat-
terning of the cell distribution and their cell-cycle status5,9.
The growth and progression of a solid tumour mass depends critically on the re-
sponses of the individual cells that constitute the entire tumour mass. The evolution
of each individual cancer cell and its decisions to grow, divide, remain inactive or die
are usually influenced by the local micro-environmental conditions at the location
occupied by any particular cell within the tumour and intracellular interactions, in-
cluding the intracellular cell-cycle dynamics. Moreover, these cellular responses are
actively influenced by various extracellular signals from neighbouring cells as well
as its dynamically changing microenvironment. As discussed in Powathil et al.5, the
growth and proliferation of each cancer cell is determined by its own internal cell-
cycle mechanism and is incorporated using a set of ordinary differential equations.
This internal cell-cycle dynamics are further influenced by the changing surround-
ing oxygen concentration which is modelled through the activation of HIF pathway
(hypoxia inducible factor pathway) linking the microenvironment to intracellular
cell-cycle pathway.
The HIF pathway in usually implicated in several hypoxia related events within
a growing tumour such as the production of metastatic phenotypes with increased
mutation rates, increased secretion of angiogenic factors, less apoptosis and an up-
regulation of various pathways involved in the metastatic cascade12. The hypoxia
inducible transcription factor -1 is composed of two subunits, HIF-1 α and HIF-1 β,
both of which are required for its transcription activation function. Under normoxic
conditions, the rapidly produced HIF-1α is degraded immediately by the actions of
proline hydroxylase and pVHL. However, under hypoxic conditions HIF-1 α escapes
degradation and its level increases rapidly. This further activates the expression of
various genes, triggering various intra- and intercellular pathways including the
expressions of cyclin dependent kinase inhibitors p21 and p27 pathways, affecting
the cell-cycle dynamics7,13. The dynamical changes in the tumour microenvironment
due to the variations in oxygen concentration are modelled using partial differential
equations. The developed model can be then used to analyse cellular heterogeneities
due to various internal and external factors and its role in a cell’s response to
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chemotherapy treatment.
2.1. Intracellular Heterogeneities: Modelling the Cell-Cycle
Dynamics
Most of the complex cellular processes that are involved in cancer progression such
as proliferation, cell division and DNA replication are regulated by the cell-cycle.
The cell-cycle is controlled by a complex hierarchy of metabolic and genetic net-
works with several transition phases of varying lengths and check points14. The
cell-cycle can be divided into four main phases: S-phase where DNA synthesis oc-
curs, G2-phase during which proteins required for mitosis are produced, M-phase
where mitosis and separation occur and G1-phase where proteins necessary for S-
phase progression are accumulated15. Additionally, cells may sometimes exit from
the cell-cycle and enter a phase of quiescence or relative inactivity called the G0-
phase or resting phase14. The cell-cycle dynamics within a mammalian cell are
regulated mainly by a family of cyclin dependent kinases (Cdk), whose activity is
primarily dependent on association with a regulatory protein called cyclin16. Ad-
ditionally, the progression of cell-cycle dynamics is affected by several intracellular
and extracellular factors such as Cdk inhibitors that can act as negative regulators
of the cell-cycle and tumour microenvironment15. A few specific examples of Cdk
inhibitors include the proteins p16, p15, p21 and p27. Some of the extrinsic fac-
tors that can influence the cell-cycle mechanism include nutrient supply, cell size,
temperature and cellular oxygen concentration14.
Here we use a cell-based modelling approach to study the growth and progression
of a cancer cell mass. The evolution of each cancer cell is based on the decisions made
by the cell-cycle mechanism within the cell and we further assume that this con-
tributes to the intracellular heterogeneities. To model the cell-cycle dynamics within
each cell, we use an adapted version of a very basic model5 originally developed by
Tyson and Novak17,18 that includes only the interactions which are considered to be
essential for cell-cycle regulation and control. The models by Tyson and Novak17,18
describe the cell-cycle as a hysteresis loop with two self-maintaining stages while
the transitions between these two stages are determined by the changing cell mass
during the division. They used kinetic relations between various chemical processes
to study the transitions between two main steady states, G1 and S-G2-M of the
cell-cycle, which is (in their model) controlled by changes in cell mass. Although,
Tyson and Novak have subsequently introduced a much more sophisticated model
for the mammalian cell-cycle19, for simplicity we have opted to use the six variable
model to simulate the cell-cycle. Moreover in the adapted model, we have used the
equivalent mammalian proteins stated in Tyson and Novak’s paper, namely the
Cdk-cyclin B complex [CycB], the APC-Cdh1 complex [Cdh1], the active form of
the p55cdc-APC complex [p55cdcA], the total p55cdc-APC complex [p55cdcT], the
active form of Plk1 protein [Plk1] and the mass of the cell [mass]5,9. Using the
kinetic relations, the evolution of the concentrations of these variables are mod-
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elled using the following system of six ODEs (further details concerning the kinetic
interactions can be found in Tyson and Novak’s papers 17,18).
d[CycB]
dt
= k1 − (k′2 + k
′′
2 [Cdh1] + [p27/p21][HIF])[CycB], (1)
d[Cdh1]
dt
=
(k
′
3 + k
′′
3 [p55cdcA])(1− [Cdh1])
J3 + 1− [Cdh1] −
k4[mass][CycB][Cdh1]
J4 + [Cdh1]
, (2)
d [p55cdcT]
dt
= k
′
5 + k
′′
5
([CycB][mass])n
Jn5 + ([CycB][mass])
n
− k6 [p55cdcT], (3)
d [p55cdcA]
dt
=
k7[Plk1]( [p55cdcT]− [p55cdcA])
J7 + [p55cdcT]− [p55cdcA]
− k8[Mad] [p55cdcA]
J8 + [p55cdcA]
− k6 [p55cdcA], (4)
d[Plk1]
dt
= k9[mass][CycB](1-[Plk1])− k10[Plk1], (5)
d[mass]
dt
= µ[mass]
(
1− [mass]
m∗
)
, (6)
where ki are the rate constants and the values are chosen in proportion to those
in Tyson and Novak so that the time scale is relevant to a mammalian cell-cycle5.
Other parameters used in the system are Ji, [Mad] and [p27/p21]
5. The effects of
changes in oxygen dynamics are included into the system through the activation and
inactivation of HIF pathway which further results in changes in cell-cycle length.
Here, we have assumed that HIF-1 α concentration at a cellular position, which
is normally inactive ([HIF] = 0), is activated ([HIF] = 1) if the oxygen concentra-
tion at that position falls below 10%. The cell-cycle inhibitory effect of p21 or p27
genes expressed through the activation of HIF-1 α is incorporated into the equation
governing our generic Cyclin-CDK dynamics, using an additional decay term pro-
portional to the concentration of p27/p21 (which is considered here as constant)5,20.
A cell is assumed to divide when the concentration of Cdk-cyclin B complex [CycB]
crosses a specific threshold value [CycB]th which is assumed to be 0.1, from above,
and then the mass, [mass] is halved. To introduce a random growth rate for indi-
vidual cells which in turn introduces cell-cycle heterogeneity in the population, we
consider a varying growth rate µ. The rest of the parameter values of the cell-cycle
model can be found in Powathil et al.5.
Figure 1 shows the changes in various protein concentrations that have been
included in the current cell-cycle model for one single automaton cell. Every cell in
this multiscale model has a similar cell-cycle dynamics built-in which further control
the division and cell-cycle phases of the respective cells. In this representative figure
(adapted from Powathil et al.5), a cell undergoes division constantly as long as there
is enough space to divide and the surrounding microenvironment is favourable for
its division. However, as soon as all its neighbouring spaces are occupied, the cell
moves to a resting phase where the concentrations are maintained at a constant
level.
November 1, 2014 15:32 Powathil&Chaplain Manuscript Powathil˙BRL˙R3
6 MAJ Chaplain and GG Powathil
Fig. 1. Plot of the concentration profiles of the various intracellular proteins and the cell-mass
over a period of 200 hours for one automaton cell in the model. This is obtained by solving the
system of equations, (1) – (6), with the relevant parameter values. Adapted from Powathil et al.5.
Fig. 2. Plot showing the concentration profile of oxygen supplied from the vasculature in the
local tissue. The red coloured spheres represent the blood-vessel cross-sections and the colour map
shows the percentages of oxygen concentration. Adapted from Powathil et al.9.
2.2. Microenvironment Heterogeneities: Modelling the Oxygen
Dynamics
The growth of individual tumour cells as well as the entire tumour mass is
externally influenced by its surrounding microenvironment. In particular the local
availability of nutrients such as oxygen. The effects of a dynamically changing mi-
croenvironment introduced by incorporating oxygen dynamics, is modelled using a
partial differential equation5,9. Here, oxygen is assumed to be supplied from a ran-
dom distribution of blood vessels (vascular cross sections in 2D) with a density of
φd = Nv/N
2, where Nv is the number of vessel cross sections in the 2-dimensional
domain (of area N2)5. This is a reasonable assumption if the blood vessels are as-
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sumed to be perpendicular to the tissue cross section of interest and there are no
branching points through the plane of interest21,22. The temporal dynamics of these
vessels are ignored at present, assuming the growth of tumour cells is much faster
than that of the vessels within the time frame of interest. Denoting by K(x, t) the
oxygen concentration at position x at time t, then its rate of change can be expressed
as,
∂K(x, t)
∂t
= ∇.(DK(x)∇K(x, t)) + r(x)m(x)− φK(x, t)cell(x, t) (7)
where DK(x) is the diffusion coefficient and φ is the rate of oxygen consumption by
a cell at position x at time t (cell(x, t) = 1 if position x is occupied by a cancer cell
at time t and zero otherwise). Here, m(x) denotes the vessel cross section at position
x (m(x) = 1 for the presence of blood vessel at position x, and zero otherwise) and
r(x) describes rate of oxygen supply5. This equation is solved using no-flux boundary
conditions and an initial condition23. Figure 2 shows a representative profile of the
spatial distribution of oxygen concentration after solving equation (7) with relevant
parameters5. Furthermore, It is observed that lack of an adequate supply of oxygen
(hypoxia) can upregulate some of the cell-cycle inhibitory proteins such as p27 and
p21 which could interfere with the cell-cycle, eventually taking the cell either to a
resting phase or inducing a cell-cycle arrest24,7. These effects are introduced into
the cell-cycle dynamics through the equation governing the changes of Cdk-cyclin
B complex (cf. Equation 1).
3. Implementation of the Multiscale Model
The tissue-scale dynamics of the oxygen concentration outlined above can be linked
to the sub-cellular and cellular changes through two different modelling approaches,
namely, (i) a hybrid multiscale cellular automaton framework5,9 and (ii) a multi-
scale cellular Potts modelling approach using the CompuCell3D framework6. In
both these modelling approaches, the computational domain contains three differ-
ent components that are required to simulate the multiscale model. These are: (1)
the cancer cells whose spatio-temporal evolution is controlled by internal cell-cycle
dynamics and the external microenvironment; (2) the oxygen concentration distri-
bution and (3) cross-sections of blood vessels from where the oxygen and chemother-
apeutic drugs are supplied to the domain of interest. A detailed explanation of these
modelling approaches are outlined below.
3.1. The Hybrid Multiscale Cellular Automaton Framework
Cellular automaton (CA) modelling has been used very extensively to model various
aspects of tumour development and progression25,21,26,27. Some examples for such
studies include multiscale tumour growth models by Alarcon et al.28, Ribba et al.29
and Gerlee and Anderson30. A brief review that discusses different CA modelling
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(a) Time =100 hr          (b) Time = 300 hr        (c) Time = 600 hr
Fig. 3. Plots of the spatial distribution of the cells in different stages of the cell cycle which are
G1 (blue), S-G2-M (green), resting (magenta), hypoxic cells in G1 (rose), hypoxic cells in S-G2-M
(yellow) and hypoxic cells in resting (silver) at times 100, 300 and 600.
approaches to study various stages of cancer progression can be found in a review
article by Moreira and Deutsch31. Recently, Powathil et al.5 developed a hybrid
multiscale cellular automaton approach to model cancer progression and used the
model to study the effects of cell-cycle dependent chemotherapeutic drugs alone and
in combination with radiation therapy5,9.
The hybrid CA model is simulated on a spatial grid of size 100×100 grid points
and each automaton element whether it is empty or occupied, has a physical size
of l × l, where l = 20 µm, simulating a cancer tissue of area 2 × 2 mm2. The
CA begins as a new grid of empty points with a single initial cell (a blue cell)
at the centre of the grid in the G1-phase of the cell-cycle. This initial cell divides
repeatedly following its internal cell-cycle dynamics and produces a cluster of cells on
a square lattice (no-flux boundary conditions are imposed). The entire multiscale
model is simulated over a certain period of time and a vector containing all cell
positions and intracellular protein levels for each cell are updated accordingly. The
oxygen dynamics are simulated using a finite difference scheme at every simulation
time step and the corresponding oxygen concentration levels are updated. The cell-
cycle phases are determined using the concentration levels of [CycB]. If [CycB]
is greater than a specific threshold (i.e. 0.1) the cell is considered to be in the
S-G2-M phase (green cell) and if it is lower than this value, the cell is in the G1-
phase. If the cyclinB-cdk complex concentration [CycB] crosses this threshold from
above, the cell undergoes cell division, its mass [mass] is halved. Alternatively, a
cell may enter into a resting phase if the dividing cell’s neighbourhood has no
space for the new daughter cell. Alternatively, if division takes place, the new cell is
placed into the G1-phase of the cell-cycle and is assigned a value for its proliferation
rate µ randomly from the range of values of µ. If there is more than one empty
space with the same oxygen concentration level, a position is chosen randomly. The
position of the new daughter cells is determined by alternating Moore and Von
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(a) Time =150 hr          (b) Time = 350 hr        (c) Time = 650 hr
Fig. 4. Plots of the spatial evolution of tumour cells in different phases of the cell-cycle at times
= 150 hr, 350 hr and 650 hr. The colour legend shows the types of the tumour cells; 1- medium,
2- G2 phase, 3- G1 phase, 4- vessel cross sections, 5- hypoxic G2 phase, 6- hypoxic G1 phase and
7- resting cells. Adapted from Powathil et al.6.
Neumann neighbourhoods to avoid generating cell distribution patterns matching
the specific neighbourhood5,9 (this creates symmetric “circular” masses of cancer
cells as opposed to square or diamond shapes). As the cancer cells proliferate, the
oxygen demand increases making an imbalance between supply and demand which
will eventually create a state where the cells are deprived of oxygen. If the oxygen
concentration falls below 10% the cells are assumed to be hypoxic and the hypoxic
cells that are in G1-phase are represented by rose colour coded cells while hypoxic
S-G2-M cells and hypoxic resting cells are denoted by the colours yellow and silver,
respectively. Figure 3 shows the distribution of cells in various cell-cycle phases at
three different time points. The simulation time step for the both the CA model and
the oxygen dynamics is taken as T=0.001 hr as it gives a oxygen diffusion constant
of 2 × 10−5 cm2/s with appropriate diffusion length scale L of 100 µm. Further
details of the model can be found in Powathil et al.5.
3.2. The Multiscale Cellular Potts Model: CompuCell3D
Framework
An alternative approach to modelling such complex multiscale problems is by using
a multiscale cellular Potts model or the Glazier-Graner-Hogeweg (GGH) approach.
The GGH model contains description of objects, such as cells and fields, interactions
with the cellular properties that evolve with respect to time and space and are mod-
elled with the help of various initial conditions32. Each cell is a collection of lattice
pixels having the same index marker and is represented as spatially extended do-
mains on a fixed lattice. We used the CompuCell3D framework developed by Glazier
et al. (see http://www.compucell3d.org for details) to simulate the previously de-
scribed multiscale model6. The multiscale model is simulated using a 2-dimensional
lattice of size 300 × 300 pixels in the x− and y−directions with an initial configu-
ration of single cells surrounded by a number of blood vessel cross sections. Similar
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to the previous approach, the division of tumour cells is driven by the cell-cycle
dynamics modelled using the kinetic equations (1)-(5). The set of ODEs governing
the cell-cycle dynamics is incorporated into the Compucell3D framework in each
Monte Carlo time step (mcs) using Bionetsolver. Bionetsolver is a C++ library that
permits easy definition of sophisticated models coupling reaction-kinetic equations
described in SBML with the defined cells for execution in CompuCell3D 32. Bionet-
solver makes use of the SBML ODE Solver Library to implement reaction-kinetic
network dynamics which can regulate the cell-cycle dynamics for each tumour cell
within the domain. Cellular growth is incorporated into the model by incrementing
the cell target volume in every mcs during growth phases at a constant rate of 0.5
times the current cell volume. Division is assumed to occur when the concentration
of [CycB] crosses the threshold value from above. However, since here we are using
a growing volume, the cell-cycle dynamics are simulated using the equations (1)-(5),
using [volume] instead of [mass]. The parameter values of the cell-cycle model are
scaled in such a way that each mcs step corresponds to 1 hour and hence a cell has
an average cell-cycle length of 25-35 hours. The evolution of oxygen concentration
is incorporated into the CompuCell3D as a diffusive chemical field that follows the
respective PDE described previously. The parameters are taken from Powathil et
al.5 and for consistency, the diffusion equation is simulated 1000 times in every 1
mcs to achieve a similar time-scale of 0.001hr 6. Figure 4 shows the spatial evolu-
tion of tumour cells. The colour of the tumour cells indicate their cell-cycle phase
position and the microenvironment status.
4. Modelling the Effects of Chemotherapy
Chemotherapy is one of the most common therapeutic options for cancer treatment,
either alone or in combination with other therapies (multimodality). Chemother-
apeutic drugs act on rapidly proliferating cells targeting the different cell-cycle
phases and check points. In cancer, Cdks, the proteins responsible for the acti-
vation of the cell-cycle, are over-expressed while cell-cycle inhibitory proteins are
under-expressed which results in a malfunctioning in the regulation of the cell-cycle,
and eventually leads to a promotion of uncontrolled growth. The rationale behind
cell-cycle, phase-specific chemotherapy is to target those proteins that are over-
expressed during various stages of cancer progression, inducing an inhibitory effect
and thus controlling cell growth. One of the major issues that affects the delivery
and effectiveness of chemotherapeutic drugs is the occurrence of cell-cycle mediated
drug resistance2. This may be due to the presence of functionally heterogeneous cells
and cell subpopulations, and can be addressed to some extent by using combinations
of chemotherapy drugs that target different phases of the cell-cycle kinetics2.
We are interested in studying the effects of cell-cycle based chemotherapeutic
drugs on cancer cells and cancer cell subpopulations with varying drug sensitivi-
ties. We model the spatio-temporal evolution of cell-cycle specific chemotherapeu-
tic drugs using a similar partial differential equation as that governing the oxygen
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Fig. 5. Plots showing the spatial evolution of tumour cells when cell-cycle phase specific
chemotherapeutic drugs are given. (i) G2 drug followed by G2 drug and (ii) G1 drug followed
by G1 drug at times (a) 510 hr, (b) 550 hr, (c) 560 hr and (d) 750 hr. Adapted from Powathil et
al.6.
dynamics. Hence, denoting by Ci(x, t) the concentration of chemotherapeutic drug
type i, its spatio-temporal evolution is given by the equation:
∂Ci(x, t)
∂t
= ∇.(Dci(x)∇Ci(x, t)) + rci(x)m(x)− φciCi(x, t)cell(x, t)− ηciCi(x, t)
(8)
where Dci(x) is the diffusion coefficient of the drug, φci is the uptake rate by a cell
(assumed to be zero), rci is the drug supply rate by the pre-existing vascular network
and ηci is the drug decay rate
5,6. As similar to that of equation governing the
oxygen concentration, this PDE is incorporated into the CompuCell3D as diffusive
chemical field and simulated using the parameters values found in Powathil et al.5.
To study the effects of multiple phase-specific chemotherapy, we consider two types
of phase-specific chemotherapeutic drugs that are either G1 specific or G2-S-M
specific, delivered at a same rate. Furthermore, chemotherapeutic drugs are assumed
to be effective in killing a cell, if its average concentration at the location of that
specific cell is above a fixed threshold value and below which the drug has no effect
on any cells. In the following subsections, we study the effects of cell-cycle based
chemotherapeutic drugs on a growing tumour using the CompuCell3D framework
hybrid multiscale computational model.
4.1. Homogenous Population Model: The Effects of Chemotherapy
In this section, we study we effects of cell-cycle based chemotherapy on a popula-
tion of homogeneously growing tumour cells with similar cell-cycle dynamics (i.e.
November 1, 2014 15:32 Powathil&Chaplain Manuscript Powathil˙BRL˙R3
12 MAJ Chaplain and GG Powathil
0 100 200 300 400 500 600 700
0
400
800
1200
1600
 
 
G1 and G1 drugs
G2 and G2 drugs
G1 and G2 drugs
G2 and G1 drugs
T
o
ta
l 
N
u
m
b
e
r 
o
f 
c
e
lls
Time (hrs)
Fig. 6. Plots comparing the total number of cells when the tumour cells are treated with two
doses of cell-cycle phase specific drugs at Time = 500 hr and Time = 550 hr. Adapted from
Powathil et al.6.
the same cell-cycle time under favourable conditions) but with intracellular and mi-
croenvironmental heterogeneities. Figure 4 shows the spatio-temporal evolution of a
solid tumour mass with a homogenous cell population in the absence of chemother-
apy. As illustrated in the figure, the colours of tumour cells indicate the cell-cycle
position and oxygenation status of each individual cell.The spatial distribution of
the tumour cells shows the development of the proliferating rim around the bound-
ary of the growing tumour as the internal cells become hypoxic due to the increased
consumption of oxygen supplied from the blood vessels.
To study the effects of cell-cycle, phase-specific chemotherapeutic drugs on the
growing tumour, two doses of cell-cycle phase-specific drugs that act on cells that
are either in G1-phase or S-G2-M phase are delivered at a same rate at times 500
hours and 550 hours. A representative figure showing the spatio-temporal evolution
of cancer cells when the tumour mass is treated with two doses of G1 drugs and G2
drugs is given Figure 5. Figure 6 shows and compares the total number of tumour
cells during the therapy. As previously shown by Powathil et al.5, the results indi-
cate that the choice and sequencing of different types of chemotherapeutic drugs can
significantly affect the spatial distribution and the cytotoxic cell-kill of cancer cells.
Furthermore, it has been shown that various factors such as the spatial distribution
of cancer cells, the correct sequencing of chemotherapeutic drugs, and intracellu-
lar and microenvironment heterogeneities play important roles in determining the
precise cytotoxic effectiveness of cell-cycle phase-specific chemotherapeutic drugs.
The results of multiple combinations of cell-cycle specific chemotherapeutic
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Fig. 7. Plots showing snapshots of the simulation results of the model with two subpopulations of
cancer cells at time points (a) 350 hr, (b) 450 hr, (c) 550 hr and (d) 650 hr. The colour legend given
in addition to that of Figure 4 (subpopulation 1) shows the types of the second subpopulation of
tumour cells; 1 - G2 phase, 2 - G1 phase, 3 - hypoxic and 4 - resting cells. Adapted from Powathil
et al.6.
drugs (Figure 6) show that a combination of G1 specific drug followed by another
G1 specific drug (Figure 5(ii)) and G2 specific drugs and G1 specific drugs give
better therapeutic outcomes than other two combinations. This is due to the pres-
ence of a higher fraction of proliferating cells in G1-phase at the time of the drug
doses and increased proliferation after the initial dose. However, please note that
these drug combinations need not always give the best outcome, especially if there
were a higher proportion of resting cells within a growing tumour mass5. Hence,
it is important to know the underlying spatial distribution of a growing tumour
mass and the internal cellular heterogeneities present to achieve the best possible
outcome.
4.2. Heterogeneous Population Model: The Effects of
Chemotherapy
One of the common reasons for chemotherapeutic failure in cancer patients is the
emergence of drug resistance in subpopulations within the growing tumour2. There
are several reasons that contribute to this chemotherapeutic drug resistance, in-
cluding multi-drug resistance to the chemotherapeutic drugs and the emergence of
heterogenous subpopulations with varying responsiveness to the given drug33,34.
Recently, it has been shown that the tumour heterogeneity caused by the cell-
cycle dynamics and the variations in the cell-cycle duration can play a vital role
in the chemotherapeutic sensitivity, as most of the chemotherapeutic drugs act on
actively cycling cells. Several studies involving heterogenous tumour masses that
contain a slowly-cycling subpopulation of tumour cells indicated that the use of
traditional chemotherapeutic drugs could ultimately lead to an emerging subpopu-
lation of drug resistant, slowly-cycling tumour cells that has the potential to repop-
ulate the tumour mass33,34. Moreover, the results from recent computational studies
using multiscale mathematical models have also confirmed the role of slowly-cycling
tumour subpopulations in developing chemotherapeutic resistance and showed that
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Fig. 8. Plots showing (a) the number of cells in various phases of the cell-cycle for a heterogenous
tumour with a second subpopulation of cells of slow-cycling tumour cells, (b) average percentage
of cells in G1/G0 and S/G2/M phases for subpopulation 1 and (c) average percentage of cells in
G1/G0 and S/G2/M phases for subpopulation 2. The lines represent the corresponding temporal
average number of cells either in G1 phase or S-G2-M phases
.
conventional chemotherapy may sometimes result in the emergence of dominant,
slowly-cycling subpopulations of tumour cells6.
Recently, Powathil et al.6 studied the chemotherapeutic effects of anti-cancer
drugs on a tumour mass that consists of two subpopulations: one with an active
cell-cycle with a cell-cycle length of 25-30 hours, and a second subpopulation with
slowly-cycling tumour cells. Figure 7 shows the spatio-temporal evolution of the
heterogenous tumour mass with two subpopulations of tumour cells. The slowly-
cycling tumour subpopulation is introduced into the previous homogenous model
(Figures 4 and 7) through random mutations that are assumed to occur after 100
mcs (hr). The quantitative results of the heterogenous tumour growth model is given
in Figure 8. Figure 8(a) compares the total number of tumour cells and the number
of cells in various phases of the cell-cycle for both subpopulations 1 and 2, and
Figures 8(b) and 8(c) give the percentage of proliferating cells in subpopulations 1
and 2. The results shown in Figures 8(b) and 8(c) indicated that the slow-cycling
subpopulation has more cells in G2 phase when compared to subpopulation 1, as
observed in previous experimental studies33,34.
The heterogenous two population tumour growth model described above can also
be used to study the effects of cell-cycle phase-specific chemotherapy6. Two doses
of cell-cycle phase-specific chemotherapeutic drugs are given at times 500 hours and
550 hours, in a similar manner to that of the homogenous case. A representative
figure for the spatial evolution of cancer cells during and after the chemotherapeutic
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Fig. 9. Plots showing the spatial evolution of tumour cells within a two population model when
cell-cycle phase specific chemotherapeutic drugs are given. (i) G2 drug followed by G2 drug and
(ii) G1 drug followed by G1 drug at times (a) 510 hr, (b) 550 hr, (c) 560 hr and (d) 650 hr. Adapted
from Powathil et al.6.
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Fig. 10. Plots showing percentage of proliferating cells in subpopulations 1 and 2. Adapted from
Powathil et al.6.
treatment with two doses of G1-phase specific drugs and G2-phase specific drugs
is shown in Figure 9. Figure 10 shows the percentage of proliferating cells in sub-
populations 1 and 2 when the tumour mass is treated with each combination of
cell-cycle phase specific chemotherapeutic drugs. A comparison of the total number
of tumour cells and the number of cells in each subpopulations is given in Figure
11 and it shows that combinations of G2 & G1 specific drugs and G1& G1 specific
drugs give a better outcome than other two combinations. Moreover, it can be seen
from Figure 10 that a second dose of G1-phase drug kills a majority of the cancer
cells in subpopulations 1 and 2, enriching the slowly-cycling cells in subpopulation
2. These results by Powathil et al.6 are in good qualitative agreement with the ex-
perimental results of Moore et al.33,34. They have shown that when a heterogenous
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Fig. 11. Plots showing the effects of cell-cycle specific chemotherapeutic drugs on the total num-
ber of tumour cells. (a) Total number of cells in two population model, (b) number of cells in
subpopulation 1 and (c) number of cells in subpopulation 2. Adapted from Powathil et al.6.
tumour mass responds positively to chemotherapeutic treatment, it kills a majority
of the active cells, increasing the percentage of slowly-cycling tumour cells within
the tumour mass (as shown in Figure 10(iv)) and thus increasing the chance for
tumour recurrence. Further extensive analysis and results of the multiscale model
for a heterogenous tumour population can be found in Powathil et al.6.
5. Conclusions
In most cases, chemotherapy is administered as a combination of multiple anti-
cancer drugs that target various processes involved in cancer growth and progres-
sion. Combination therapy is usually used to increase the cytotoxicity and mostly
targets various intracellular biochemical concentrations that are fluctuating during
the cell-cycle, aiming to reduce the drug resistance due to the heterogenous nature
of the tumours, with minimal toxicity. However, the efficacy of these administered
chemotherapeutic drugs is often influenced by the intracellular perturbations of the
cell-cycle dynamics, inducing a cell-cycle-mediated drug resistance. Hence, it is very
important to study and analyse the underlying heterogeneity within a cancer cell
and within a solid tumour mass due to the presence of the microenvironment and the
cell-cycle position so as to design and develop more effective treatment protocols.
In this article, we have presented a multiscale mathematical model incorporating
the effects of intracellular cell-cycle dynamics and the external microenvironment to
study the spatio-temporal dynamics of tumour growth and its response to cell-cycle
based chemotherapy5,6. The developed multiscale mathematical model can be imple-
mented using various computational approaches. Here, the multiscale mathematical
model is implemented using two hybrid individual-based approaches, namely: (i) a
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hybrid cellular automaton approach5,9 and (ii) a hybrid cellular potts approach us-
ing the CompuCell3D framework6. Although each of these modelling approach is
technically different, the results obtained from both multiscale models are similar
and comparable, showing the robustness of the multiscale mathematical modelling
approach. Recently, several experimental and clinical observations14,33,34 have in-
dicated the role of internal and external heterogeneities in inducing chemothera-
peutic drug resistance within a growing tumour, increasing its chances of recur-
rence. We have further used the multiscale computational model (using the Com-
pucell3D framework) to study the effects and efficacy of chemotherapy on a ho-
mogeneously growing tumour with intracellular heterogeneities and a heterogenous
tumour growth model (with a slowly-cycling tumour subpopulation) with intracel-
lular heterogeneities. The results obtained from the multiscale model were in very
good agreement with the previous experimental findings6,33,34 and highlighted the
role of intrinsic cell-cycle-driven drug resistance of slowly-cycling tumour subpopu-
lation in the recurrence of the tumour after therapy. Future work will consider other
factors that may induce drug resistance within a growing tumour mass such as vari-
ations in cell cycle control, anti-apoptotic proteins, multi-drug resistance through
the activation of cellular pumps and increased metabolic activities33,35,4 to study
their role in tumour recurrence and analyse the various optimum delivery protocols
for multiple chemotherapeutic drugs to achieve maximum therapeutic benefit.
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